According to the price announced by the National Medical Insurance Bureau, 40mg of oxytinib is in 300 yuan and 80mg is in 5 10 yuan. 80mg is equivalent to 1.53 million per month, and the reimbursement rate of Class B drugs in medical insurance is between 60% and 80%. The monthly personal expenditure is about 3 100-6 100 yuan.
● Oxytinib.
Oxytinib is suitable for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (non-small cell lung cancer), who have developed diseases before or after EGFR-TKI therapy and have been confirmed to have EGFR-T790M mutation. As the third generation EGFR-TKI drug, the emergence of osetinib solved the drug resistance problem of the first and second generation lung cancer patients in time. In the past, patients treated with second-line oxitinib can be reimbursed through medical insurance to reduce the economic burden. Now the Medical Insurance Bureau has announced that patients who use oxytinib in the first line can also be reimbursed by medical insurance, but this year oxytinib is included in medical insurance.
● Medical insurance reimbursement is difficult.
On the one hand, the price reduction of anti-cancer "magic medicine" oxytinib reduces the economic burden of patients and their families, on the other hand, it also gives patients confidence to overcome the disease. However, it is not easy to apply for medical insurance reimbursement for ositinib, and there are conditions.
First, through genetic testing, it is confirmed that there are patients with non-small cell lung cancer who are resistant to the first-generation drugs gefitinib, erlotinib and Kemena and have T790M positive mutation.
Second, patients who want to reimburse oxytinib need to provide relevant medical history data and examination reports. After being confirmed by the doctor in charge of special drugs, you can get a "special drug certificate" and buy related drugs in special drug pharmacies.
● Before being included in medical insurance
For patients who have no medical insurance and do not meet the requirements, they can only choose 5880 yuan/box of oxitinib, which is unbearable for ordinary families. Therefore, many families choose the Indian oxitinib, which is a generic drug, but it has the same efficacy as the authentic oxitinib, and each box costs only 1000 yuan. In fact, India does not have an imitation version of _ Hitinib, and due to the perfection of Indian patent law, India cannot imitate _ Hitinib. However, the Indian market also has _ Hitinib, which is actually the Bangladeshi version of its neighbor _ Hitinib.
Indian (Bangladeshi version) oxitinib is only about 1000 yuan, and the therapeutic effect is no less than that of the original factory, and the raw materials are exactly the same as the original factory. It is precisely because of this that so many patients choose India (Bangladesh version) oxytinib, a cheap and effective targeted drug that patients dream of.